After a mostly red week, stocks gapped higher Friday morning with the latest jobs report. The jobless rate fell to 5.
Gilead Sciences, Inc. (NASDAQ:GILD) has been rolling in the money since the release of its hepatitis C drug duo, Sovaldi and Harvoni.
In a research report released Friday, Canaccord Genuity analyst Adam Walsh initiated coverage on shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) with a Buy rating and …
It’s been an eventful week on the pipeline front with companies like Biogen Inc (NASDAQ:BIIB), Prothena Corporation PLC (NASDAQ:PRTA) and Vertex Pharmaceuticals Incorporated …
In a research report published Thursday, Needham analyst Alan Carr downgraded shares of Vertex Pharmaceuticals (NASDAQ:VRTX) from Buy to Hold, following the company’s fourth-quarter financial results, which were …
In a research report published Monday, JP Morgan analyst Cory Kasimov maintained an Overweight rating on Vertex Pharmaceuticals (NASDAQ:VRTX) with a price target …
J.P.
In a research note sent to investors today, J.P.
2014 has been an eventful year on Wall Street. Now that the year is coming to an end, what stocks should investors be …
In a research report published Monday, Maxim Group analyst Jason Kolbert reiterated a Buy rating on Vertex Pharmaceuticals (NASDAQ:VRTX) and raised his price …
